Event in Progress:
Discover the latest content that has just been published on Research Tree
After completing the 1:20 share consolidation, OpGen has announced a $7.5m equity issue to be closed by 11 January 2023. As part of the offering, OpGen will issue 2.6m common shares (or pre-funded warrants) at $2.90 per share, along with a similar number of Series A-1 and A-2 warrants. The warrants will be exercisable immediately at a strike price of $2.65 per share with respective expiry dates of five years and 18 months. OpGen plans to use the funds raised to accelerate commercialization effor
Companies: OpGen Inc (OPGN:NYSE)OpGen, Inc. (OPGN:NAS)
Edison
Following a proposed share consolidation announced in November 2022, OpGen has effected a reverse stock split in the ratio of 1:20. This comes in the wake of a Nasdaq notification received in late August 2022 granting the company a 180-day extension (ending in February 2023) to regain compliance with its listing requirements (minimum threshold price of $1 per share). Given Nasdaq’s liquidity and trading volumes, we see Opgen’s ability to maintain the listing as crucial to its effectiveness in ra
OpGen’s valuation case rests on its ability to develop and commercialize its suite of differentiated diagnostic products, focused on combating anti-microbial resistance (AMR). Q322 was marked by several developments on this front (see our last note), albeit offset with market caution in the current macroeconomic environment. This resulted in revised FY22 guidance (revenue of $2.5–3.0m versus c $4.6m previously) with the Q322 results. The delayed sales cycle conversions, along with the regulatory
OpGen has announced encouraging final data from its Unyvero Urinary Tract Infection (UTI) panel, a diagnostic test designed to detect pathogens and antimicrobial resistance markers related to UTI, from native urine specimens without the need for culturing. The study, which recruited over 1,800 patient samples across four trial sites in the United States, met its primary endpoint with an overall weighted average sensitivity of 96.4% and specificity of 97.4% in preliminary analysis. The favourable
OpGen’s Q322 revenues of $0.4m missed consensus estimates (following a strong Q222 performance), with management attributing the softness to longer than expected sales cycles for ARES and lower Unyvero A50 sales in international markets. Encouragingly though, the quarter was marked by business advancements – signing a second Acuitas AMR Gene Panel commercial contract, completing the UTI test panel patient enrollment in the US, launching ARES sequencing services in the US and announcing collabora
The penultimate quarter of FY22 for OpGen was marked by tangible progress in advancing its pipeline, although revenue realization was lower than anticipated at c $0.4m in Q322 (attributed to a lower-than-expected contribution from ARES). Key milestones achieved during the quarter were the signing of a second commercial contract for the Acuitas AMR Gene Panel, completion of patient enrollment for the UTI test panel in the US, launch of ARES sequencing services in the US and collaborations with FI
OpGen has announced a collaboration agreement with Swiss pharma company, BioVersys, for the use of the Unyvero platform in screening patients for the enrollment of BioVersys’ upcoming Phase II clinical trial of drug candidate BV100. Unyvero’s HPN panel, an integrated sample-to-answer pneumonia cartridge, will be used for detecting a range of pathogens and AMR markers in hospitalized pneumonia patients. This collaboration expands the utilization of the Unyvero platform and OpGen’s overall franchi
OpGen has completed patient sample enrollment in its prospective multicenter trial for the Unyvero urinary tract infection (UTI) panel in the United States, taking the company closer to commercializing another Unyvero test panel, following the lower respiratory tract infection (LRT) and the LRT bronchoalveolar lavage tests in 2018 and 2019, respectively. OpGen reported that more than 1,800 samples have been collected across four sites in the United States as part of the study, exceeding the FDA-
OpGen has announced a $3.38m (gross) fund-raising through a private placement to an existing healthcare-focused institutional investor. This is in exchange for a combined 9.66m of common stock and pre-funded warrants at $0.35/unit plus an additional 33.8k shares of series C preferred stock. The investor was also issued warrants to purchase up to an aggregate of 9.66m in common stock, at an exercise price of $0.377/share. The offer is expected to close on 3 October 2022 and is subject to sharehol
OpGen has announced an R&D collaboration with FIND (a global non-profit alliance for diagnostics) and the German KfW bank for its Unyvero A30 RQ platform for pathogen identification (ID) and antimicrobial resistance (AMR testing) using blood culture samples. Phase I of the R&D collaboration will involve a feasibility study, expected to conclude by end Q123. FIND will invest €700k in the study with the option to extend the collaboration, including a potential commercialisation agreement in low- a
OpGen has announced the launch of its next-generation sequencing (NGS) services in the United States at its new Rockville-based service laboratory. The NGS lab, developed by its subsidiary Ares Genetics, offers short-turnaround genome sequencing of clinical isolates, artificial intelligence (AI) powered outbreak analysis that can be conveniently accessed through the company’s AREScloud web application. The closer proximity to a large US customer base allows OpGen to better leverage its Ares Gene
OpGen’s Q222 revenue growth re-accelerated with the post-pandemic normalization in demand. Revenues of $0.97m increased 19% y-o-y, largely driven by strength in its core offering, Unyvero. Management announced several notable wins that provide momentum to close the back half of the year strong, including the signing of two commercial Acuitas AMR Gene Panel contracts, extension of the Unyvero distribution agreement with Menarini in Europe, new distribution agreements in the Middle East and Kosovo
OpGen’s subsidiary, Ares Genetics, has signed a research collaboration agreement with the Belgian National Reference Center (BNRC) for invasive Streptococcus pneumoniae at the university hospital Leuven. Under the agreement, the partners will evaluate the utility of Ares Genetics’ next-generation sequencing platform, machine learning tools and bioinformatics to identify and characterize Streptococcus pneumoniae for diagnostic purposes. This agreement marks Ares Genetics’ second collaboration wit
OpGen provided a business update including preliminary top-line Q222 results. Quarterly revenues of $1.0m increased 23.2% y-o-y from $0.8m in Q121 and 113% from the previous quarter. Management highlighted several key developments, including the first commercial contract for the Acuitas AMR Gene Panel, extension of the existing distribution agreement with European distribution partner Menarini, a new distribution agreement with Leader Life Sciences for UAE and Qatar, and an at-the-market (ATM) s
Research Tree provides access to ongoing research coverage, media content and regulatory news on OpGen, Inc.. We currently have 27 research reports from 2 professional analysts.
Companies: hVIVO plc
Liberum
On 10 January last year, we set out our ten top stock picks for 2022, in what turned out to be a very poor twelve months for global equities, due to war, accelerating inflation, political instability and recession fears. Between 7 January 2022 and 31 December 2022, the AIM All-Share Index declined 30.0%, whilst the average performance of our ten top picks was -24.7%, a modest relative outperformance. In this note we discuss the performance of our 2022 top picks, equities trends in 2022, and our
Companies: GHH SCE BGO TPT ZOO ASTO INCH DWF EQLS NXR
Zeus Capital
Companies: Jet2 PLC
Canaccord Genuity
Performance - 2022 ended with another difficult month for property companies as the sector continues to get to grips with the impact of higher interest rates. There were several funds that performed well during December, however, with secondary shopping centre landlord Capital & Regional top of the pile. For a second month on the trot Home REIT saw its share price tank after it came under attack from a short seller in November. Valuation moves - It was a mixed bag for valuations, with six-month
Companies: GWW GWW TOWN API RLE LMP CAPC WHR CSH ASLI PCA EBOX RGLZ ESP PHP SHED SRE MLI RGL CRC CBA DELMUR
QuotedData Professional
Companies: ITM IOG KOD AVCT
Kemeny Capital
RBGP has published its FY22 pre-close trading update this morning. Unaudited FY22 revenue, adj. EBITDA and adj. operating profit are expected to be in-line with our estimates. Professional Services, saw good performances across both, the legal services and sell-side corporate finance offering. Whilst there is no resolution on decreasing exposure to LionFish, the Group is encouraged by accelerating developments. RBGP also announced a number of changes to the board, with Nicola Foulston, CEO, havi
Companies: RBG Holdings Plc
Singer Capital Markets
Companies: Begbies Traynor Group plc
Shore Capital
Cenkos Securities plc has terminated coverage on Bidstack Group Plc. Our previous recommendation (BUY) and forecasts can no longer be relied upon. Please contact Cenkos for further information.
Companies: Bidstack Group Plc
Cenkos Securities
25 January 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment object
Companies: FNX GHE HVO HVO KWS WJG OTMP CRCL EPWN 2018
Hybridan
17 January 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment object
Companies: RNO WINE CNS HVO HVO RFX KIBO
23 January 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment object
Companies: CFX SUN LDSG GTC SIS TST EMAN SHED BOOM
Franchise Brands held a well-attended CMD yesterday which highlighted the group's strategy, the robust performance of its two key operating divisions (B2B and Filta International), and how the application of technology and effective marketing are driving growth.
Companies: Franchise Brands plc
Dowgate Capital
hVIVO issued a positive trading update for FY 2022, citing revenues (including other income) of £50.6m, which was above its previous guidance of £50m and FC’s revenue forecast of £49.1m, EBITDA margins not less than 17% and period-end cash of £28.4m (FC £22.8m est). Whilst this performance was positively affected by the recognition of postponement and cancellations fees amounting to c.£1m, underlying EBITDA was c.£7.6m (9% above FC £7.0m est) implying margins were c.15%, towards the top end of i
finnCap
Companies: Inspired PLC
20 January 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment object
Companies: GHE AGY MIRI SLE DSW BIG
Share: